Rapamycin - Effects on Alzheimer's and Cognitive Health
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, and feasibility of 12 month oral rapamycin
treatment in older adults with amnestic mild cognitive impairment (aMCI) and early stage
Alzheimer's disease (AD).
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio